Safety
nail disorder, hypophosphatemia, toxicity, TEAEs, hyperphosphatemia
NAIL DISORDER, HYPOPHOSPHATEMIA, ADVERSE EVENTS, HYPERPHOSPHATEMIA, EVENTS
All patients experienced TEAEs (Table Most common treatment-emergent adverse events (occurred in ≥ 25% of all patients)Adverse events were classified according to All patients experienced at least one sponsor-defined clinically-notable TEAE, all being grade 1 or 2 in severity, including hyperphosphatemia (12/12, 100%), hypophosphatemia (3/12, 25.0%), nail toxicity (2/12, 16.7%), nail disorder (2/12, 16.7%) and nail discolouration (1/12, 8.3%).